BCAX – bicara therapeutics inc. (US:NASDAQ)
Stock Stats
News
Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics (NASDAQ:BCAX) is now covered by analysts at Citizens Jmp. They set a "market perform" rating and a $31.00 price target on the stock.
Bicara Therapeutics (NASDAQ:BCAX) is now covered by analysts at Citigroup Inc.. They set an "outperform" rating on the stock.
Bicara Therapeutics (NASDAQ:BCAX) had its "buy" rating reaffirmed by analysts at BTIG Research.
Form 8-K Bicara Therapeutics Inc. For: Feb 19
Form SCHEDULE 13G/A Bicara Therapeutics Inc. Filed by: Vestal Point Capital, LP
Form SCHEDULE 13G Bicara Therapeutics Inc. Filed by: T. Rowe Price Investment Management, Inc.
Form SCHEDULE 13G Bicara Therapeutics Inc. Filed by: Deep Track Capital, LP
Form SCHEDULE 13G/A Bicara Therapeutics Inc. Filed by: FMR LLC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.